CA3246779A1 - SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND THEIR PREPARATION METHOD - Google Patents

SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND THEIR PREPARATION METHOD

Info

Publication number
CA3246779A1
CA3246779A1 CA3246779A CA3246779A CA3246779A1 CA 3246779 A1 CA3246779 A1 CA 3246779A1 CA 3246779 A CA3246779 A CA 3246779A CA 3246779 A CA3246779 A CA 3246779A CA 3246779 A1 CA3246779 A1 CA 3246779A1
Authority
CA
Canada
Prior art keywords
compound
salt
free base
degrees
hci salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246779A
Other languages
English (en)
French (fr)
Inventor
Gerald Kleymann
Christian Gege
Original Assignee
Innovative Molecules GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovative Molecules GmbH filed Critical Innovative Molecules GmbH
Publication of CA3246779A1 publication Critical patent/CA3246779A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3246779A 2022-01-17 2023-01-16 SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND THEIR PREPARATION METHOD Pending CA3246779A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22151820.2 2022-01-17
EP22151820 2022-01-17
EP22170332 2022-04-27
EP22170332.5 2022-04-27
PCT/EP2023/050883 WO2023135303A1 (en) 2022-01-17 2023-01-16 Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof

Publications (1)

Publication Number Publication Date
CA3246779A1 true CA3246779A1 (en) 2023-07-20

Family

ID=84982261

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246779A Pending CA3246779A1 (en) 2022-01-17 2023-01-16 SOLID CRYSTALLINE FORMS OF HELICASE-PRIMASE INHIBITORS AND THEIR PREPARATION METHOD

Country Status (12)

Country Link
US (1) US20250115565A1 (cg-RX-API-DMAC10.html)
EP (1) EP4466255A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025502300A (cg-RX-API-DMAC10.html)
KR (1) KR20240134979A (cg-RX-API-DMAC10.html)
AU (1) AU2023206628A1 (cg-RX-API-DMAC10.html)
CA (1) CA3246779A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024002124A1 (cg-RX-API-DMAC10.html)
IL (1) IL314188A (cg-RX-API-DMAC10.html)
MX (1) MX2024008821A (cg-RX-API-DMAC10.html)
PY (1) PY2302301A (cg-RX-API-DMAC10.html)
UY (1) UY40111A (cg-RX-API-DMAC10.html)
WO (1) WO2023135303A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4580601A1 (en) * 2022-08-29 2025-07-09 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
IL325911A (en) 2023-07-17 2026-03-01 Innovative Molecules Gmbh Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds
WO2026078039A1 (en) 2024-10-09 2026-04-16 Innovative Molecules Gmbh Oral administration forms of antiviral helicase-primase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
PH12018501979B1 (en) 2016-04-06 2023-05-05 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
PL3692039T3 (pl) 2017-10-05 2023-04-17 Innovative Molecules Gmbh Enancjomery podstawionych tiazoli jako związki przeciwwirusowe
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
AU2021367976A1 (en) 2020-10-29 2023-06-08 Innovative Molecules Gmbh Deuterated aminothiazole compounds as antiviral compounds

Also Published As

Publication number Publication date
CL2024002124A1 (es) 2024-11-22
IL314188A (en) 2024-09-01
UY40111A (es) 2023-08-15
PY2302301A (es) 2023-10-31
US20250115565A1 (en) 2025-04-10
WO2023135303A1 (en) 2023-07-20
TW202337444A (zh) 2023-10-01
EP4466255A1 (en) 2024-11-27
MX2024008821A (es) 2024-07-29
KR20240134979A (ko) 2024-09-10
AU2023206628A1 (en) 2024-08-01
JP2025502300A (ja) 2025-01-24

Similar Documents

Publication Publication Date Title
US20250115565A1 (en) Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof
TWI729530B (zh) 吡咯并〔2,3-d〕嘧啶甲苯磺酸鹽類、其晶形以及其製造方法及中間體
JP7407171B2 (ja) グリコシダーゼ阻害剤として有用なピペラジン誘導体のコハク酸付加塩及びフマル酸付加塩
US11834443B2 (en) Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
BR112019020840A2 (pt) sais farmacêuticos, formas físicas e composições de inibidores da pirrolopirimidina quinase e métodos de produção dos mesmos
US20150183779A1 (en) Solid state form of vemurafenib choline salt
JP2020525475A (ja) N−[1−(5−シアノ−ピリジン−2−イルメチル)−1h−ピラゾール−3−イル]−2−[4−(1−トリフルオロメチル−シクロプロピル)−フェニル]−アセタミドの結晶形
JP2023552274A (ja) 抗ウイルス化合物としての重水素化アミノチアゾール化合物
AU2023270440A1 (en) Crystal forms of triazine dione derivative and preparation method therefor
CN114075169B (zh) 奥希替尼药用共晶体及其制备方法
CN121532378A (zh) 抗病毒解旋酶-引发酶抑制剂化合物的微粉化结晶盐酸盐
CN114728982A (zh) 固体形式的s1p-受体调节剂
CN118556045A (zh) 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法
EA052003B1 (ru) Твердые кристаллические формы ингибиторов геликазы-примазы и способ их получения
EP3481801B1 (en) Indoline derivatives and method for using and producing the same
HK40110051A (en) Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof
TW202330496A (zh) 用於製備大麻素受體調節劑之結晶形式及方法
US20250304635A1 (en) Birinapant polymorph h
RU2787767C2 (ru) Кристалл производного бензоксазола
TW201908320A (zh) 一種btk激酶抑制劑的結晶形式及製備方法
JP2025528116A (ja) 5,6-ジヒドロチエノ[3,4-h]キナゾリン類化合物の塩型、結晶型およびその調製方法
JP2023524622A (ja) 6-クロロ-7-(4-(4-クロロベンジル)ピペラジン-1-イル)-2-(1,3-ジメチル-1H-ピラゾール-4-イル)-3H-イミダゾ[4,5-b]ピリジンの塩及び多形体
HK40054619B (en) Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto
US20090076038A1 (en) Deuterium-enriched entecavir

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240704

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241121

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241121

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241125

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251112

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251112